DALLAS, June 25, 2026
Taysha Gene Therapies announced multiple presentations highlighting the clinical progress of its investigational TSHA-102 gene therapy at the 2026 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting, taking place from June 29 to July 1 in Prior Lake, Minnesota. The presentations feature longer-term REVEAL Part A Phase 1/2 clinical data, natural history analyses, endpoint validation research, and new preclinical findings supporting the design of TSHA-102 for Rett syndrome. Recently disclosed clinical results demonstrated broad, multi-domain functional improvements that continued to deepen through at least 12 months after a single treatment, regardless of patient age or disease severity, reinforcing the therapy’s potential to address the underlying genetic cause of this rare neurodevelopmental disorder.
Clinical and Natural History Data Strengthen REVEAL Pivotal Trial Strategy
New analyses presented by the company show that Rett syndrome patients reach a clear developmental plateau after approximately six years of age, providing a stable patient population for evaluation in the planned REVEAL pivotal trial. Additional research supports the Rett Syndrome Developmental Milestone Assessment (RS-DMA) as a psychometrically validated and FDA-supported primary endpoint suitable for single-arm interventional studies. These findings strengthen the clinical development strategy for TSHA-102, offering regulators and investigators a reliable method to measure meaningful functional improvements while addressing the significant unmet medical need for disease-modifying therapies in Rett syndrome.
Preclinical Findings Support TSHA-102 Gene Therapy Design
Taysha also presented new preclinical data demonstrating that its self-complementary AAV9 vector produces superior MeCP2 expression compared with conventional single-stranded AAV approaches. The research showed that the company’s gene therapy design enables efficient central nervous system (CNS) delivery through intrathecal administration, supporting broad therapeutic distribution while maintaining controlled expression of the MECP2 protein. TSHA-102 incorporates Taysha’s proprietary miRNA-Responsive Auto-Regulatory Element (miRARE) technology, which is designed to regulate MECP2 levels on a cell-by-cell basis and minimize the risk of overexpression, an important consideration in developing safe gene replacement therapies for Rett syndrome.
Advertisement
Multiple Regulatory Designations Support TSHA-102 Development
TSHA-102 continues to receive strong regulatory recognition as it advances through clinical development. The investigational therapy has been granted Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Orphan Drug, and Rare Pediatric Disease designations by the U.S. Food and Drug Administration (FDA), along with Orphan Drug designation from the European Commission and Innovative Licensing and Access Pathway (ILAP) designation from the UK Medicines and Healthcare products Regulatory Agency (MHRA). With multiple scientific presentations scheduled throughout the IRSF meeting, Taysha Gene Therapies aims to further demonstrate the growing clinical evidence supporting TSHA-102 as a potential one-time gene therapy capable of addressing the genetic root cause of Rett syndrome, a devastating rare disease that currently has no approved disease-modifying treatment.
Source: Taysha Gene Therapies press release
